Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Expenses (2016 - 2025)

Editas Medicine (EDIT) has disclosed Accumulated Expenses for 11 consecutive years, with $47.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 65.09% to $47.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $47.5 million, a 65.09% increase, with the full-year FY2024 number at $45.9 million, up 32.68% from a year prior.
  • Accumulated Expenses was $47.5 million for Q3 2025 at Editas Medicine, down from $48.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $48.1 million in Q2 2025 to a low of $5.5 million in Q2 2021.
  • A 5-year average of $27.2 million and a median of $28.8 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: plummeted 68.11% in 2023, then soared 331.52% in 2024.
  • Editas Medicine's Accumulated Expenses stood at $20.2 million in 2021, then skyrocketed by 54.99% to $31.3 million in 2022, then grew by 10.44% to $34.6 million in 2023, then surged by 32.68% to $45.9 million in 2024, then grew by 3.63% to $47.5 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Accumulated Expenses are $47.5 million (Q3 2025), $48.1 million (Q2 2025), and $47.5 million (Q1 2025).